Mangoceuticals, Inc.
MGRX
$2.14
-$0.19-8.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 53.80% | 3.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 53.80% | 3.90% | |||
| Cost of Revenue | 65.68% | 88.05% | |||
| Gross Profit | 44.77% | -22.47% | |||
| SG&A Expenses | 50.23% | 100.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 50.43% | 42.38% | |||
| Operating Income | -50.33% | -44.09% | |||
| Income Before Tax | -11.91% | -148.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.91% | -148.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -100.00% | -50.00% | |||
| Net Income | -11.91% | -148.38% | |||
| EBIT | -50.33% | -44.09% | |||
| EBITDA | -43.29% | -81.69% | |||
| EPS Basic | 48.51% | 2.11% | |||
| Normalized Basic EPS | 49.70% | -41.73% | |||
| EPS Diluted | 48.51% | 2.11% | |||
| Normalized Diluted EPS | 49.70% | -41.73% | |||
| Average Basic Shares Outstanding | 117.36% | 75.26% | |||
| Average Diluted Shares Outstanding | 117.36% | 75.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||